Form 4 for RIGL RIGEL PHARMACEUTICALS INC
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0000905148-26-000953 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-17 | RIGL | Rojkjaer Lisa | EVP, Chief Medical Off | A - Grant | $0.00 | +18.9K | 34.9K | +118% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | A | A | 18,894 | $0.00 | 34,853 | D | — | — | (F1) The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. |